What Cloben Treats: Main Uses and Benefits

Dual Management of Inflammatory Fungal Infections

The combination medication is primarily used in situations involving certain distressing symptoms of common fungal skin infections, such as ringworm (Tinea Corporis), jock itch (Tinea Cruris), and athlete's foot (Tinea Pedis). It is applicable in conditions where the fungal component is accompanied by visible, distracting skin inflammation. The product is relevant in contexts marked by increased discomfort and is commonly used for managing inflamed fungal infections with symptoms of redness or itching.

Relief of Intrusive Itching and Dermal Distress

The medication helps address symptom clusters that may become intense or disruptive, particularly intense itching (pruritus) and the associated burning or irritation. This is relevant for easing symptoms that interfere with daily comfort. The dual focus assists with managing both the infectious and inflammatory aspects of the condition. It provides support that helps ease the overall symptom burden and contributes to easing the overall symptom load during periods of symptomatic escalation.

Quick Fact: Relevant for Symptomatic Inflammatory States

Regulatory References

1. Official FDA Label via DailyMed

Who can and cannot use Cloben?

The eligibility for this combination product is strictly defined by regulatory documents, focusing on patient age, known sensitivities, and specific co-existing conditions. This information outlines who is permitted to use the medicine under standard conditions and who is officially excluded, based on potential risks from the corticosteroid component.

Populations Prohibited from Use (Contraindicated) The medication must not be used in patients with a known hypersensitivity to Betamethasone Dipropionate, Clotrimazole, or any related corticosteroid or imidazole antifungal. Use is also contraindicated in the presence of certain untreated viral skin diseases (e.g., Herpes Simplex or Varicella), bacterial skin infections, or skin tuberculosis.

Age and Conditional Restrictions

Population Group	Eligibility Status	Key Restriction
Adults	Eligible	17 years of age and older.
Pediatric Patients	Not Recommended	Use is not recommended for patients under 17 years due to the higher risk of systemic absorption.
Pregnancy/Lactation	Conditional Use	Caution is advised; use on the smallest possible area for the shortest duration.

Additionally, the medication is not recommended for treating Diaper Dermatitis or for use under occlusive dressings. Patients with pre-existing conditions such as Diabetes or a risk of glaucoma or HPA axis suppression must also use the medicine with caution.

Cloben Interactions with other medicines and products

Cloben is a product name often associated with the antifungal medicine clotrimazole, which is available in various formulations for topical use (e.g., cream, liquid, vaginal tablet), sometimes combined with other agents like corticosteroids or antibiotics (e.g., Cloben-G).

Since topical use results in minimal systemic absorption, the risk of significant drug-drug interactions with other orally or systemically administered medicines is generally considered low. However, interactions can occur, especially with specific formulations or if the medicine is used over large areas or for extended periods.

Documented Pharmacokinetic Interactions

• Enzyme Inhibition: Clotrimazole, a component in Cloben, is known to interact with the cytochrome P450 enzyme system, specifically CYP3A4. When used in systemic (non-topical) forms, this can lead to clinically significant interactions by slowing the metabolism of certain other medicines, potentially increasing their concentration and risk of side effects.

Specific Interacting Medicines and Products

Classification	Interacting Agents	Context/Mechanism
Increased Concentration	Tacrolimus (oral), Sirolimus (oral)	Systemic clotrimazole may increase blood levels of these immunosuppressants, requiring careful therapeutic drug monitoring.
Increased Bleeding Risk	Warfarin and other Coumarin anticoagulants	Clotrimazole may enhance the effects of these agents, increasing the risk of bleeding.
Effectiveness Impairment	Latex-containing Contraceptives (Condoms, Diaphragms)	Vaginal formulations containing clotrimazole can damage the latex material, leading to a loss of contraceptive efficacy. Alternative, non-latex barrier methods are advised for at least five days after treatment.

Patients should inform their healthcare provider about all prescription drugs, over-the-counter products, and supplements being used to fully assess the risk of potential interactions.

Action on Local Inflammatory Signaling

The corticosteroid component acts as an agonist at intracellular glucocorticoid receptors. This binding facilitates the complex's entry into the cell nucleus, where it modulates gene expression and inhibits the synthesis of pro-inflammatory signals such as cytokines and chemokines. This cascade leads to the physiological outcome of dampening the overactive local immune response, which results in a decrease in capillary permeability and dilation at the site of application.

Disruption of Fungal Cell Structure

The antifungal component functions as an inhibitor of lanosterol 14alpha-demethylase, a key enzyme in the fungal cell. This inhibition blocks the crucial biosynthesis of ergosterol, a lipid essential for maintaining the cell membrane's structural integrity. This mechanistic action causes structural instability in the fungal cell, resulting in the impairment of cell viability or destruction of the fungal organism.

Inhibiting Bacterial Protein Synthesis

The antibacterial component acts as an inhibitor by binding selectively to bacterial ribosomal subunits. This interference blocks the formation of crucial peptides, thereby stopping the replication and survival of the bacteria. This mechanism results in a reduction of the bacterial population at the site of application.

Administration Scope and Labeled Regimen

Cloben (Clotrimazole and Betamethasone Dipropionate) is formulated for topical use only and is supplied as a cream or lotion. The administration route is strictly confined to the skin surface; the product is not intended for ophthalmic, oral, or intravaginal use.

The standard adult regimen involves applying a thin film of the cream to the affected skin area twice daily, typically scheduled for the morning and evening.

Treatment Duration and Constraints

The duration of therapy is defined by the site of application:

Application Site	Standard Duration	Maximum Duration
Tinea Corporis (Ringworm)	1 week	2 weeks
Tinea Cruris (Jock Itch)	1 week	2 weeks
Tinea Pedis (Athlete's Foot)	2 weeks	4 weeks

Treatment should generally not exceed the prescribed duration, and a maximum total dose of 45 grams per week should not be exceeded. If there is no improvement after one week for tinea corporis or tinea cruris, or after two weeks for tinea pedis, it is generally recommended that the diagnosis be reviewed.

Special Procedural Instructions

The cream requires no preparation and should be gently massaged into the affected skin. Occlusive dressings (such as tight bandages or wraps) should not be used over the treated area unless specifically advised by a healthcare professional. Use is generally not recommended in patients under the age of 17 years. If a dose is missed, it should be applied as soon as the patient remembers, and the normal twice-daily schedule should be resumed; two doses should not be applied at the same time.

Research evidence / Overview of Studies for Cloben

This section summarizes the structure and reported findings from authorized clinical research, primarily based on official studies and regulatory reviews. It describes what the research has explored and what remains uncertain.

---

Evidence for Use in Inflamed Ringworm and Jock Itch (Tinea Corporis / Tinea Cruris)

Research was studied for conditions characterized by fluctuating or episodic manifestations of tinea corporis and tinea cruris where noticeable inflammation, such as redness and itching, was present. The primary body of research reviewed included short-term Randomized Controlled Trials (RCTs) that examined adults with culture-confirmed infections caused by common dermatophytes.

These studies monitored two main outcomes related to physical discomfort: patient-reported symptom scores and the laboratory evidence of fungal elimination (mycological cure). Some trials described that measurements of clinical response at early follow-up visits differed between the combination product group and the group receiving the antifungal agent alone. Conversely, the studies monitored the final mycological cure rates at the end of the observation period, and findings were reported as being in a similar range for both groups.

---

Research Focused on Symptom Relief vs. Fungal Clearance

Research examined the role of the corticosteroid component on outcomes capturing phases of heightened symptom activity, such as itching and redness. Findings describe patterns observed in the studies; for instance, some research highlighted that changes measured during the study period for clinical symptoms differed between the combination formulation group and the antifungal agent alone group.

Conversely, the evidence contributes to the broader evidence landscape by showing that the final clearance of the fungal infection was often similar between the combination product and the antifungal monotherapy. Research provides context but not individual predictions regarding which outcome axis will be observed first.

---

Areas of Research Uncertainty and Gaps

Long-term effects are not fully established. There is limited information for long-term outcomes, including the effect of the combination on preventing recurrence. Comparative evidence is lacking for the combination against the full range of alternative, newer single-agent antifungal medications.

The combination product was evaluated primarily for the adult population (17 years and older). Data for certain groups remain insufficient, particularly for children younger than 17 years old, who have not been included in sufficient numbers in the pivotal clinical studies.

Common questions about Cloben (FAQ)

Q: Does Cloben cause drowsiness or affect the ability to drive?

Regulatory documents do not typically list drowsiness as a common side effect for this topical medicine.

However, in rare instances, absorption of the drug through the skin can potentially lead to systemic effects. Signs associated with these more serious systemic effects, such as dizziness or feeling very tired, have been reported in official documentation.

Q: Is Cloben safe to use during pregnancy according to regulatory bodies?

According to the official product information, this combination drug is assigned to Pregnancy Category C by the FDA.

This classification indicates a general requirement for the potential benefit to justify the potential risk to the fetus before use is initiated.

Q: Does Cloben interact with common pain relievers like ibuprofen?

Official drug safety literature suggests that when the corticosteroid component (Betamethasone) is absorbed into the bloodstream, using it alongside Nonsteroidal Anti-inflammatory Drugs (NSAIDs) like ibuprofen may potentially increase the risk of certain gastrointestinal side effects.

Q: What are the official restrictions for using Cloben on sensitive areas of the body?

Official documentation describes that the product is not recommended for application on areas such as the face or underarms.

This is primarily due to the potential for greater absorption and the risk of localized side effects in areas where the skin may be thinner.

Q: Can Cloben be used in patients with kidney or liver issues?

Official labeling notes that patients with liver impairment or liver failure are described as being at increased risk for systemic side effects.

This is due to potential changes in how the body processes and eliminates the absorbed drug components, which can affect the overall amount circulating in the body.

Q: Can Cloben be used to treat skin conditions other than the primary one it's prescribed for?

The medicine has specific approved indications for use defined by regulatory bodies.

Official documents state that the product is indicated only for the topical treatment of specific fungal dermal infections: tinea pedis, tinea cruris, and tinea corporis. It is explicitly not recommended for other skin conditions such as rosacea or perioral dermatitis.

Q: What should I do if I think I've used too much Cloben?

Official guidelines define a maximum total dose limit to reduce the risk of systemic absorption.

Using amounts that exceed this limit, or applying the medicine over large areas, increases the risk of serious systemic side effects, notably affecting the adrenal glands (HPA axis suppression).

Q: Is there a generic version of Cloben available?

Records from the FDA and other regulatory bodies confirm that generic versions of the combination product (which contains Betamethasone and Clotrimazole) are available.

Q: Does using Cloben affect the results of any common medical tests?

Official labeling mentions that systemic absorption of the corticosteroid component has been reported to produce changes in lab values in some patients.

These changes may include hyperglycemia (high blood sugar) and glucosuria (sugar in the urine).

Q: What are the main ingredients, besides the active drug, listed in Cloben products?

The final product contains inactive components, or excipients, in addition to the two active drug ingredients.

The full and specific list of these non-active ingredients is provided in the official labeling for each specific formulation, such as the cream or lotion.

Q: Are there specific instructions for washing hands before or after using Cloben?

The Patient Information Leaflet specifies that washing hands both before and after applying the cream is a general instruction.

This is noted as an expected procedure unless the treatment area happens to be located on the hands themselves.

How to Store and Dispose of Cloben (Beclometasone/Clotrimazole)

The storage and disposal of this combination topical medicine must adhere strictly to official regulatory requirements to maintain its integrity.

Storage Conditions

Official labeling mandates that the product be stored at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F). It is a mandatory requirement to keep the product from freezing and to protect it from excessive heat, light, and moisture. The medicine must remain in its original container, tightly closed.

Safety and Disposal

Regulatory instructions require that this medication be stored out of the reach of children and pets. For disposal, unused or expired medication must not be released into the environment, meaning it should not be flushed down a toilet or poured down a drain. Disposal should follow instructions from a healthcare professional or national authority regarding appropriate waste removal.